Background We sought to investigate the prevalence of mucocutaneous
manifestations (MCM) and potential associations with clinical
characteristics in Greek patients with IBD. Methods This was a
retrospective observational single-center study. Patients with IBD
diagnosis attending a tertiary referral hospital in Heraklion, Crete,
from January 2010 to January 2020 were included. Data were extracted
with relevant medical information from the IBD registry. Standard
statistical tests, descriptive statistics tests, chi-square, Pearson
correlation and multivariate analysis tests were performed, using IBM
SPSS Statistics 25. Results A total of 806 IBD patients were included in
the study: 463 (57.4%) males, 441 (54.7%) Crohn’s Disease, 352
(43.7%) ulcerative colitis and 13 (1.6%) IBD unclassified (IBD-U).
Mean age was 50.67 +/- 17.67 years, mean age of IBD diagnosis 36.67 +/-
16.53 years and mean disease duration 13.65 +/- 9.89 years. The
prevalence of MCM was 171/806 (21.2%), 9.65% in ulcerative colitis and
30.84% in CD. The presence of MCM was significantly correlated with
younger age of IBD diagnosis, longer IBD duration, CD diagnosis,
inflammatory behavior and ileal or ileocolonic location of CD, extensive
colitis in ulcerative colitis, intestinal manifestations (EIMs) and
treatment with immunosuppressant or anti-TNFa. The development of MCM
was independently associated with the presence of other EIMs odds ratio
(OR), 4.03 [95% confidence interval (CI), 2.60-6.24; P < 0.001] and
treatment with immunosuppressant (OR, 1.87; 95% CI, 01.14-3.07; P =
0.013) or anti-TNFa (OR = 2.47; 95% CI, 1.59-3.84; P < 0.01).
Conclusions In our study, about one-fifth of IBD patients developed MCM
that was more frequently present in CD than in ulcerative colitis